Status:
COMPLETED
Substance Misuse To Psychiatric Disorders for Cannabis
Lead Sponsor:
The University of Hong Kong
Collaborating Sponsors:
Queen Mary Hospital, Hong Kong
Conditions:
Cannabis Use Disorder
Depressive State
Eligibility:
All Genders
16-50 years
Phase:
PHASE2
PHASE3
Brief Summary
With the recent availability of vortioxetine, and the surging phenomenon of cannabis misuses amongst young abusers, it is a timely opportunity to conduct an early pharmacotherapy intervention study to...
Eligibility Criteria
Inclusion
- • Cannabis use disorder with anxiety or depressive symptoms or disorders; or positive cannabis test results in 1 month with anxiety or depressive symptoms
Exclusion
- Age \<16 years old
- Unable to read English or Chinese
- Unable to give informed consent
- Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation
- Had history of primary psychotic episode
- Had been diagnosed to have substance-induced mood disorder, other than cannabis
- Had been diagnosed to have mood disorders or anxiety disorders
- Had been taking maintenance therapeutic dose of antidepressant continuously \>= 6 months AND with depressive symptom or anxiety symptom being in remission
- Had known hypersensitivity to vortioxetine
- Had known history of serotonin syndrome
- Pregnant
- Mother currently breast-feeding
- Currently taking warfarin and/or having poorly controlled bleeding disorder
- Had history of prolonged QTc ≥500ms and/or known unstable or untreated cardiology disease
Key Trial Info
Start Date :
July 25 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2023
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT03485274
Start Date
July 25 2018
End Date
April 30 2023
Last Update
July 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital
Hong Kong, Hong Kong, 000000